Reza Mohebi
Internal Medicine · San Francisco, CANPI 1891292280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,781 of the $3,335 with a category attached, or 83.4%. Boehringer Ingelheim International GmbH accounts for 83.4% of it on its own, with 13 other manufacturers making up the rest.
Across 21 payments — averaging $158.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$3K
- Novo Nordisk$97
- Xeris Pharmaceuticals, Inc.$56
- Lilly USA, LLC$56
- Amgen$55
- Pfizer$55
- plus $237 from 8 others
Across 3 payments — averaging $59,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$141K
- AstraZeneca$24K
- Pfizer$15K
What the payments were for
- Speaking & faculty fees$2,78183%
- Food & beverage$45814%
- Education$973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 1 | $2,781 |
| Novo Nordisk | 3 | $97 |
| Xeris Pharmaceuticals, Inc. | 2 | $56 |
| Lilly USA, LLC | 2 | $56 |
| Amgen | 2 | $55 |
| Pfizer | 2 | $55 |
| GSK | 2 | $39 |
| Grifols USA, LLC | 1 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $33 |
| Exact Sciences | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$2,781
How this compares
$3,335 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 12 | $261 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.